Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, MN 55901, USA.
Am J Ther. 2011 May;18(3):261-5. doi: 10.1097/MJT.0b013e3181b7b8c0.
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease that is associated with considerable morbidity and mortality. The disease etiopathogenesis has not been well defined. Several observations suggest that portal bacteremia or chronic bile duct infection may be factors that could play a role in the pathogenesis of the disease. Clinical trials have tested different treatments for PSC but without convincing evidence of benefit. Liver transplantation is the only available therapeutic option that is thought to be beneficial for PSC. Antibiotics have been used in several case series over the years to treat PSC and have had, in some cases, impressive benefits when compared with other drugs used for treating the disease. We gathered the available data for different antibiotics used in PSC in this review. Further studies are needed to support the efficacy of using antibiotics for PSC patients.
原发性硬化性胆管炎（PSC）是一种慢性胆汁淤积性肝病，与相当高的发病率和死亡率相关。该疾病的发病机制尚未明确。一些观察结果表明，门静脉菌血症或慢性胆管感染可能是在疾病发病机制中起作用的因素。临床试验已经测试了不同的 PSC 治疗方法，但没有令人信服的获益证据。肝移植是唯一被认为对 PSC 有益的治疗选择。抗生素多年来在多个病例系列中被用于治疗 PSC，与用于治疗该疾病的其他药物相比，在某些情况下具有显著的获益。我们在本综述中收集了 PSC 中使用的不同抗生素的现有数据。需要进一步的研究来支持抗生素治疗 PSC 患者的疗效。
